CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the Virtual Investor Closing Bell Series. The event will take place on Wednesday, June 17, 2024, at 4:00 PM ET.

CEO John Climaco will provide a corporate overview and answer questions from participants during the live video webcast. Interested parties can access the event through the Company's website, with a replay available for 90 days following the presentation.

This virtual event offers an opportunity for investors and stakeholders to gain insights into CNS Pharmaceuticals' current developments and future plans in the field of cancer treatment.

Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17^th at 4:00 PM ET

HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in the Virtual Investor Closing Bell Series on Wednesday, June 17, 2024 at 4:00 PM ET.

As part of the event, Mr. Climaco will provide a corporate overview. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Climaco will answer as many questions as possible in the time allowed.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.

CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-4717-8247
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

When is CNS Pharmaceuticals (CNSP) participating in the Virtual Investor Closing Bell Series?

CNS Pharmaceuticals (CNSP) is participating in the Virtual Investor Closing Bell Series on Wednesday, June 17, 2024, at 4:00 PM ET.

Who will be presenting at the Virtual Investor Closing Bell Series for CNS Pharmaceuticals (CNSP)?

John Climaco, the Chief Executive Officer of CNS Pharmaceuticals (CNSP), will be presenting at the Virtual Investor Closing Bell Series.

What will be discussed during CNS Pharmaceuticals' (CNSP) presentation at the Virtual Investor Closing Bell Series?

John Climaco will provide a corporate overview of CNS Pharmaceuticals (CNSP) and answer questions from participants during the live video webcast.

How can investors access CNS Pharmaceuticals' (CNSP) presentation at the Virtual Investor Closing Bell Series?

Investors can access the live video webcast of CNS Pharmaceuticals' (CNSP) presentation on the Events page of the Investors section of the Company's website (cnspharma.com).

How long will the replay of CNS Pharmaceuticals' (CNSP) Virtual Investor Closing Bell Series presentation be available?

The replay of CNS Pharmaceuticals' (CNSP) presentation will be available for 90 days following the live event.